I am in the process of negotiating a clinical trial agreement with
Wyeth-Ayerst and we have come to "the wall" on the issue of IDC (what else?).
The company says the following:  "It is now Wyeth-Ayerst policy to limit the
reimbursement of institutional overhead to no more than 20 percent".  Has
anyone dealt with Wyeth-Ayerst recently and come up against this policy?
Any luck getting them to go higher?  Our institutional policy is 25% and I am
very reluctant to accept "business" at a rate lower than that, but at the same
time I am reluctant to walk away from a sizable contract.  Either reply
via resadm-l or send a personal message to me at the e-mail address shown
below.   THANKS!

Doug Wilkerson, Ph.D.           VOICE:  (419) 381-4252
Assoc. V.P. for Research        FAX:    (419) 381-4262
Professor of Pharmacology       e-mail: xxxxxx@GEMINI.MCO.EDU
Medical College of Ohio
3000 Arlington Ave.
Toledo, OH 43614